Nursing Pharmacology:  Antiviral Drugs

Previous Page Page Forward
Section Table of Contents
Site Table of Contents
Section Table of Contents
Site Table of Contents

References

  1. Flexner C Antiretroviral Agents and Treatment of HIV Infection, Chapter 59  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  2. Fauci AS Lane HC Chapter 189, Human Immunodeficiency Virus Disease:  AIDS and Related Disorders, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012.

  3. Longo DL Fauci AS  188, The Human Retroviruses, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012.

  4. Safrin S Antiviral Agents, Chapter 49 in Basic & Clinical Pharmacology, 12 e (Katzung BG Masters SB Trevor AJ) The McGraw-Hill Companies, 2012 (on-line edition).

  5. Cochrane A Retroviruses Chapter 28 in Fundaments of Molecular Virology, 2e, Acheson NH, ed., John Wiley & Sons pp 342-353 2011.

  6. Cochrane A Human Immunodeficiency Virus Chapter 29  in Fundaments of Molecular Virology, 2e, Acheson NH, ed., John Wiley & Sons pp 354-364 2011.

  7. Ryan KJ, Ray C. Chapter 18. Retroviruses: Human T-Lymphotropic Virus, Human Immunodeficiency Virus, and Acquired Immunodeficiency Syndrome. In: Ryan KJ, Ray C. eds. Sherris Medical Microbiology (Part editor, Ahmad N Ray CG Drew WL), 5e. New York, NY: McGraw-Hill; 2010.

  8. Panteleo G Graziosi Fauci AS The Immunopathogenesis of Human Immunodeficiency Virus Infection (Mechanism of Disease, Epstein FH, ed) The New England Journal of Medicine 328(5) 327-335, 1993.

  9. NIH/HIAID:  "Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor."http://commons.wikimedia.org/wiki/File:Healthy_Human_T_Cell.jpg

  10. Lyumkis D Julien J-P de Val N Cupo A Potter CS Klasse P-J Burton DR Sanders RW Moore JP Carragher B Wilson IA Ward B Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer.  Science 342: 1484-1490, 20 December 2013.

  11. McLellan JS Pancera M Carrico C Gorman J Julien J-P Khayat R Louder R Pejchal R Sastry M Dai K O'Dell S Patel N Shahzah-ul-Hussan S Yang Y Zhang B Zhou T Zhu J Boyington JC Chuang G-Y Diwanji D Georgiev I Kwon YD Lee D Louder MK Moquin S Schmidt SD Yang Z-Y Bonsignori M Crump JA Kapiga SH Sam NE Haynes BF Burton DR Koff WC Walker LM Phogat S Wyatt R Orwenyo J Wang L-X Arthos J Bewley CA Mascola JR Nabel GJ Schief WR Ward AB Wilson IA Kwong PD Structure of HIV-1gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343 (followed by detailed Methods section and additional references) 15 December 2011.

  12. Chen B Vogan EM Gong H Skehel JJ Wiley DC Harrison SC Structure of an unlignaded simian immunodeficiency virus gp120 core. Nature 433:  834-841, 24 February, 2005. https://microbewiki.kenyon.edu/index.php/HIV_Envelope_and_Cell_Fusion

  13. Zhang M Gaschen B Blay W Foley B Haigwood N Kuiken C Korber B Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins:  HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14(12): 1229-1246, 2004. http://glycob.oxfordjournals.org/content/14/12/1229.full

  14. Chohan B Lang D Sangar M Korber B Lavreys L Richardson B Overbaugh J Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels. Journal of Virology 79(10): 6528-6531, May 2005.

  15. Derdeyn CA Decker JM Bibollet-Ruche F Mokili JL Muldoon M Denham SA Heil ML Kasolo F Musonda R Hahn BH Shaw GM Korber BT Sallen S Hunter E Envelope-Constrained Neutralization-Sensitive HIV-1 after Heterosexual Transmission. Science, New Series, 303(5666) 2019-2022, Mar. 26, 2004.

  16. Keele BF Giorgi EE Salazar-Gonzalez JF Decker JM Pham KT Salazar MG Sun C Grayson T Wang S Li H Wei X Jiang C Kirchherr JL Gao F Anderson JA Ping L-H Swanstrom R Tomaras GD Blattner WA Goepfert PA Kilby JM Saag MS Delwart EL Busch MP Cohen MS Montefiori DC Haynes BF Gaschen B Athreya GS Lee HY Wood N Seoighe C Perelson AS Bhattacharya T Korber BT Hahn B Shaw GM.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. (US) 105(21) 7552-7557, May 27, 2008.

  17. AIDS.gov  Stages of HIV Infection https://www.aids.gov/hiv-aids-basics/just-diagnosed-with-hiv-aids/hiv-in-your-body/stages-of-hiv/index.html

  18. Haase AT Perils at Mucosal Front Lines for HIV and SIV and their Hosts.  Nature Reviews|Immunology 5: 783-792 October 2005.

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.